Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Healthtrust
Dow
Queensland Health
Colorcon
QuintilesIMS
US Army
Cerilliant
Fish and Richardson

Generated: June 21, 2018

DrugPatentWatch Database Preview

ORPHENADRINE CITRATE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Orphenadrine Citrate, and what generic alternatives are available?

Orphenadrine Citrate is a drug marketed by Akorn, Sagent Pharms, Watson Labs, West-ward Pharms Int, Ascot, Gavis Pharms, Impax Pharms, Invagen Pharms, Sandoz, Tedor Pharma Inc, and Stevens J. and is included in fifteen NDAs.

The generic ingredient in ORPHENADRINE CITRATE is aspirin; caffeine; orphenadrine citrate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
Drug patent expirations by year for ORPHENADRINE CITRATE
Pharmacology for ORPHENADRINE CITRATE
Synonyms for ORPHENADRINE CITRATE
(+-)-N,N-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate
(+-)-N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1)
2-hydroxypropane-1,2,3-tricarboxylic acid; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
4596-23-0
4682-36-4
A826945
AB2000458
AC1L3690
AC1Q74TZ
AK117797
AKOS008132385
AN-903
C18H23NO.C6H8O7
C24H31NO8
CAS-4682-36-4
CCG-40242
CHEBI:7790
CHEMBL1200395
citric acid; N,N-dimethyl-2-[o-tolyl(phenyl)methoxy]ethanamine
CITRIC ACID; ORPHENADRINE
citro; orphenadrine
CPD000058817
CS-2426
CTK7J1567
D00774
DSSTox_CID_24678
DSSTox_GSID_44678
DSSTox_RID_80390
DTXSID8044678
EINECS 225-137-5
EN300-53019
Ethanamine, N,N-dimethyl-2-((2-methylphenyl)phenyl)methoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Ethanamine, N,N-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Ethanamine, N,N-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Ethylamine, N,N-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)-, citrate (1:1)
Euflex
Flexon
Flexor
FT-0655842
FT-0673305
HMS1920D10
HMS2091L10
HMS2231J06
HMS3259M21
HMS3370M12
HMS3651A10
HMS502K15
HY-B0369A
I06-1758
LS-175025
MCULE-5864907407
MLS000069549
MolPort-003-666-248
N,N-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate
N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1)
N,N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
N,N-Dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
N,N-dimethyl-2-[(2-methylphenyl)-phenyl-methoxy]ethanamine; 2-oxidanylpropane-1,2,3-tricarboxylic acid
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; 2-hydroxypropane-1,2,3-tricarboxylic acid
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
N,N-dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
NC00525
NCGC00015771-13
NCGC00094745-01
NCGC00094745-02
NCGC00094745-03
NCGC00254980-01
NE62567
Norflex (pharmaceutical)
NSC-757238
NSC757238
OR026096
OR272303
ORPHENADINE CITRATE
Orphenadrine (Citrate)
Orphenadrine citrate (Norflex)
Orphenadrine citrate (USP)
Orphenadrine Citrate [USAN]
Orphenadrine dihydrogen citrate
Orphenadrinecitrate
Pharmakon1600-01500447
Plenactol
SAM002554918
SAM002589900
SCHEMBL119470
SMR000058817
SPECTRUM1500447
ST51053224
Tega-Flex
Tox21_111323
Tox21_111323_1
Tox21_113543
Tox21_301079
X-Otag

US Patents and Regulatory Information for ORPHENADRINE CITRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn ORPHENADRINE CITRATE orphenadrine citrate INJECTABLE;INJECTION 040484-001 May 24, 2006 AP RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Gavis Pharms ORPHENADRINE CITRATE orphenadrine citrate TABLET, EXTENDED RELEASE;ORAL 040284-001 Jun 19, 1998 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs ORPHENADRINE CITRATE orphenadrine citrate INJECTABLE;INJECTION 087062-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Tedor Pharma Inc ORPHENADRINE CITRATE orphenadrine citrate TABLET, EXTENDED RELEASE;ORAL 040249-001 Jan 29, 1999 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
AstraZeneca
Farmers Insurance
Queensland Health
Cerilliant
Boehringer Ingelheim
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.